Cardiomyopathy Trial, Recruiting NCT04257994 Sponsor: St. George's Hospital, London Condition: Cardiomyopathy
Back to Cardiomyopathy

Trial results

This trial has reported results on ClinicalTrials.gov. A plain-English summary is being prepared; in the meantime you can read the reported results directly at the links below.

These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.

Cardiomyopathy Trial, Recruiting

NCT04257994
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with a hereditary heart rhythm or heart muscle condition — such as arrhythmogenic, hypertrophic, or dilated cardiomyopathy, cardiac sarcoidosis, Long QT syndrome, Brugada syndrome, or catecholaminergic polymorphic ventricular tachycardia (CPVT) — and are being seen at the Inherited Cardiac Conditions (ICC) service at St. George's University Hospitals NHS Foundation Trust.
  • Family members of someone who died suddenly from a suspected heart condition, where that family member is being assessed at the same clinic for risk and diagnosis.
  • People who have clear signs of one of these conditions based on standard heart tests (such as ECGs, echocardiograms, cardiac MRI, or Holter monitoring), as well as people who carry a relevant gene change but may not yet show any obvious symptoms.
  • People currently receiving any type of treatment for their condition, including medications, implanted devices, or surgery — all are eligible to participate.
  • People who have other health conditions alongside their heart condition — their full medical history would be taken into account.
  • Adults aged 18 and over.
  • Pregnant women — the study methods used are described as non-harmful and non-invasive.
  • People who have read the study information and signed a consent form agreeing to take part.

Who may not be able to join:

  • People under 18 years of age.
  • People who are not able to make their own informed decisions about participating.
  • People who have a heart condition that is not hereditary or not related to heart rhythm — for example, heart disease caused by blocked arteries or inflammatory heart conditions — even if they are seen at St. George's University Hospitals NHS Foundation Trust.
  • People who do not speak English, unless a translator is available who can fully explain the study so that informed consent can be properly given.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Angeliki Asimaki, St George's, University of London

Phone: 02087252817

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
St. George's Hospital, London
Registry
ClinicalTrials.gov
Start date
15 October 2017
Est. completion
30 March 2024

Where this trial is recruiting

🇬🇧 United Kingdom

Primary endpoints

Alteration of Key Protein Distribution

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov